Lexicon Pharmaceuticals | LXRX - Nettoeinkommen





Nettoeinkommen Veränderung Datum
Abbott USD 928M 149M 2026-06
Acadia Pharmaceuticals USD 3.64M 269.93M 2026-03
Agios Pharmaceuticals USD -99.11M 8.93M 2026-03
Akebia Therapeutics USD -12.24M 12.78M 2025-12
Alnylam Pharmaceuticals USD 164.49M 41.5M 2026-06
AstraZeneca USD 2.51B 573M 2026-06
BioMarin Pharmaceutical USD 105.53M 152.1M 2026-03
Coherus Biosciences USD -37.64M 2.11M 2025-12
Eli Lilly USD 7.4B 760M 2026-03
Halozyme Therapeutics USD 150.05M 291.64M 2026-03
Illumina USD 134M 200M 2026-03
Insmed USD -163.56M 164.92M 2026-03
Ironwood Pharmaceuticals USD 3.19M 457K 2024-12
J&J USD 5.53B 299M 2026-06
Lexicon Pharmaceuticals USD -15.53M 2.76M 2025-12
MacroGenics USD -36.77M 22.62M 2026-03
MannKind USD -15.95M 23.93M 2025-12
Merck USD -4.24B 7.2B 2026-03
Moderna USD -1.34B 517M 2026-03
Novartis USD 3.26B 108M 2026-06
PTC Therapeutics USD -2.81M 132.16M 2026-03
Puma Biotechnology USD 20.32M 24.85M 2024-09
Sarepta Therapeutics USD 330.96M 743.18M 2026-03
Thermo Fisher Scientific USD 1.74B 85M 2026-06
Ultragenyx Pharmaceutical USD -185M 56M 2026-03
United Therapeutics USD 274.9M 89.4M 2026-03
Vanda Pharmaceuticals USD -18.9M 13.58M 2024-12